. Introduction {#s01}
==============

Lung cancer is one of the most common malignant tumors in the world. According to the data from GLOBOCAN 2012, 1.8 million people are diagnosed with lung cancer every year, which represents 13% of all newly diagnosed cancer patients. Lung cancer is also the number one cause of cancer-related death, accounting for 1.6 million deaths per year, which represents 19% of all cancer deaths^[@b1]^. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and constitutes approximately 85% of all lung cancer cases. Studies have shown that the disruption of normal epigenetic regulation is an important mechanism in the initiation and progression of cancer^[@b2]^. Research has also indicated that the Wnt/β-catenin signaling pathway is critical in tumorigenesis^[@b3]^.

DNA methylation plays a crucial role in the epigenetic regulation of gene activity and function^[@b4]-[@b6]^. Substantial alterations in DNA methylation and gene expression have been observed in many types of cancer, including breast^[@b7]^, prostate^[@b8]^, and lung^[@b9]^ cancer. It has also been reported that the downregulation of the Wnt/β-Catenin signal inhibitors by hypermethylation is common in NSCLC^[@b10]-[@b13]^. Recently, Zhang et al.^[@b14]^ found that *TMEM88* could inhibit canonical Wnt/β-Catenin signaling through interaction with the Wnt pathway factor Dishevelled (DVLS). *TMEM88*, located on chromosome 17p13.1, is a transmembrane protein that plays an important role in embryonic development and stem cell differentiation^[@b15]^. However, it remains unclear whether *TMEM88* hypermethylation in lung cancer has any biological relevance to tumorigenesis and if this has any clinical implications for disease prognosis.

In this study, we investigated the role of *TMEM88* methylation in NSCLC with regard to its association with the clinical and pathological features of patients with NSCLC. Using the demethylation agent DAC, we evaluated the methylation and expression of *TMEM88* in lung cancer cells and its impact on cancer cell migration, invasion, proliferation, and cell cycle progression. We also analyzed the association of *TMEM88* methylation with the overall survival of patients with NSCLC.

. Materials and methods {#s02}
=======================

. Patients {#s02.01}
----------

Patients with NSCLC were recruited from the Tianjin Medical University Cancer Hospital (TMUCH) between May 2006 and July 2011. The fresh tumor samples and adjacent non-tumor tissues were collected from the patients during the surgical resection of tumors. Twelve pairs of tumor and adjacent non-tumor samples were used for microarray analyses of DNA methylation and gene expression. For validation, an additional 213 tumor samples and 30 matched adjacent non-tumor tissues were analyzed for methylation by using bisulfite pyrosequencing; further, the gene expression of 201 tumor samples and 66 matched adjacent non-tumor tissues was tested by using qRT-PCR; and, from these two batches, samples from 173 patients were analyzed for both the methylation and expression of *TMEM88*. The clinical and pathological information for each patient was extracted from hospital medical records and pathology reports. All patients were followed after surgery until August 2013. The study was approved by the Medical Ethical Review Committees at Tianjin Medical University Cancer Institute and Hospital and Shanghai Jiao Tong University School of Public Health.

. RNA extraction and qRT-PCR {#s02.02}
----------------------------

Total RNA was extracted from the tissue samples and cultured cancer cells by using a commercial kit. Quantitative RT-PCR assays were performed as previously described^[@b16]^.

. DNA extraction and analysis of DNA methylation {#s02.03}
------------------------------------------------

Genomic DNA was extracted from the tissue samples and cancer cells by using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany, Cat no. 51304). The extracted DNA samples were treated with sodium bisulfite by using the EpiTect plus DNA Bisulfite Kit (Qiagen, Cat no. 59124) according to the manufacturer's protocol. Genome-wide DNA methylation profiles were measured in 12 pairs of tissue samples by using the Illumina HumanMethylation450 BeadChip (Illumina, Cat no. WG-314-1003); the procedure for the microarray analysis of DNA methylation has been described elsewhere^[@b14]^. Bisulfite pyrosequencing was performed to validate our microarray results from tissue samples. For pyrosequencing, the treated DNA samples were amplified by PCR and fragmented. The processed samples were then precipitated, suspended, and genotyped in the Pyro Mark Q96 system (Qiagen, Hilden, Germany). The sequencing primers were designed to include CpG sites within 0.5 kb of the transcription start site. A methylation level of 15% or higher was considered positive for methylation and any levels equal to or lower than that were considered undistinguishable from the background.

. Cell culture {#s02.04}
--------------

The NSCLC cell lines A549 and H1299 were purchased from Cell Bank of Chinese Academy of Sciences (Cell Bank of CAS, Cat nos. TCHu150 and TCHu160) and maintained in RPMI-1640 medium at 37 °C supplemented with 10% fetal calf serum (Sigma, Cat no. F2442) in a humid atmosphere containing 5% CO~2~, as recommended by CAS. For the experiments that evaluated cell behavior, cells in the exponential growth phase were used.

. Treatment with 5-aza-2'-deoxycytidine (DAC) {#s02.05}
---------------------------------------------

NSCLC cells in culture were treated with 10 μM/L 5-aza-2'-deoxycytidine (DAC) (Sigma-Aldrich, Cat no. A3656) for 72 h. After treatment, the cells were harvested to extract genomic DNA and total RNAs for use in gene expression analysis and DNA methylation. For the experiments involving DAC treatment, DMSO was used as the control treatment.

. Assays for cell proliferation, migration, invasion, and cell cycle progression {#s02.06}
--------------------------------------------------------------------------------

Cell proliferation was analyzed by using Cell Counting Kit-8 (Dojindo, Cat no. CK04, Japan). After DAC treatment for 0 h, 24 h, and 48 h, the cells were treated with 10% CCK-8 in new media for 2 h at 37 °C and the absorbance at 450 nm was measured. Cell migration was measured by using a wound healing assay in 6-well plates. After the cultured cells reached full confluence, a 100-μL pipette tip was used to scrape a line in each well. The images of the cultures were taken at 72 h after DAC treatment. The invasion assay was performed by using Transwell chamber inserts (Corning, USA) with Matrigel according to the manufacturer's protocol. Cell cycle progression was analyzed by C6 flow cytometer (BD, Cat no. 653160).

For details, please refer to the protocols described in our previous publication^[@b16]^.

. siRNA transfection {#s02.07}
--------------------

The transfection assays of *TMEM88* siRNA were performed according to the protocols described in our previous publication^[@b17]^.

. Statistical analysis {#s02.08}
----------------------

SPSS software version 16.0 was used for the computation of statistical analyses. Student's *t*-test was performed to compare changes in cell-based experiments. Chi-squared tests were used to analyze *TMEM88* methylation and expression in association with clinical and pathological parameters. The Kaplan-Meier survival curves and log-rank tests were used to evaluate the association between methylation and overall survival. Cox proportional-hazards regression, in which covariates and confounding factors were adjusted, was also used for multivariate survival analysis. The overall survival time was calculated from the date of surgery to the date of death or last live contact. Pearson's correlation coefficient was calculated to assess the correlation between the expression of *TMEM88* and the genes involved in the Wnt signaling pathway by using data from TCGA (The Cancer Genome Atlas). All statistical tests were based on two-tailed analysis.

. Results {#s03}
=========

. *TMEM88* expression and methylation in NSCLC {#s03.01}
----------------------------------------------

In our microarray analyses of DNA methylation and gene expression, we found that *TMEM88* was hypermethylated in 12 NSCLC tumors compared with 12 matched adjacent non-tumor samples and that the methylation was inversely correlated with the expression of *TMEM88* (**[Figure. 1A](#Figure1){ref-type="fig"}**). High methylation in the *TMEM88* promoter region was confirmed in additional 213 tumor samples compared with 30 adjacent non-tumor tissues by using bisulfite pyrosequencing. A low expression of *TMEM88* was validated in 201 tumor samples in comparison with 66 adjacent non-tumor tissues by using qRT-PCR. The inverse correlation between methylation and expression was also validated in 173 subjects (*P*=0.001) (**[Figure. 1B](#Figure1){ref-type="fig"}**), which supported the results of the microarray analyses.

![Correlation between *TMEM88* expression and methylation, and the association *TMEM88* expression and methylation with NSCLC overall survival.](cbm-14-4-377-1){#Figure1}

. *TMEM88* and NSCLC characteristics {#s03.02}
------------------------------------

The methylation and expression of *TMEM88* associated with the clinical and pathological features of NSCLC are shown in **[Table 1](#Table1){ref-type="table"}**. The analysis indicated that *TMEM88* methylation was associated with tumor size and histology (*P*=0.002 and *P*=0.010, respectively). However, neither *TMEM88* methylation nor expression were associated with patient age at diagnosis, gender, BMI, family history of lung cancer, smoking status, and disease stage (**[Table 1](#Table1){ref-type="table"}**).

###### 

Associations of *TMEM88* methylation and expression with patient clinical and pathological features

  Characteristics            Group     Methylation                       Expression                                                              
  -------------------------- --------- ------------- --------- --------- ------------ ----------- -- ----- --------- --------- --------- ------- -------
  Age (years)                ≤ 60      213           56 (54)   47 (46)   1.364        0.243                201       50 (51)   48 (49)   0.046   0.831
  \> 60                      51 (46)   59 (54)                 51 (50)   52 (50)                                                                 
  Stage                      I-II      208           74 (53)   65 (47)   0.868        0.351          197   58 (48)   64 (52)   0.943     0.331   
  III-IV                     32 (46)   37 (54)                 41 (55)   34 (45)                                                                 
  BMI                        ≤ 24      212           59 (52)   55 (48)   0.162        0.687          199   48 (49)   51 (51)   0.126     0.723   
  \> 24                      48 (49)   50 (51)                 51 (51)   49 (49)                                                                 
  Gender                     Male      213           58 (47)   66 (53)   1.422        0.233          201   65 (52)   61 (48)   0.242     0.623   
  Female                     49 (55)   40 (45)                 36 (48)   39 (52)                                                                 
  History of lung diseases   No        213           97 (50)   98 (50)   0.223        0.637          201   94 (51)   91 (49)   0.294     0.588   
  Yes                        10 (56)   8 (44)                  7 (44)    9 (56)                                                                  
  Family history             No        212           90 (51)   88 (49)   0.004        0.952          200   81 (50)   81 (50)   0.085     0.770   
  Yes                        17 (50)   17 (50)                 20 (53)   18 (47)                                                                 
  Smoking status             No        213           43 (57)   33 (43)   1.902        0.168          201   25 (42)   34 (58)   2.072     0.150   
  Yes                        64 (47)   73 (53)                 76 (54)   66 (46)                                                                 
  Histology                  LUSC      185           40 (42)   55 (58)   6.683        **0.010**      167   52 (53)   47 (47)   0.776     0.378   
  LUAD                       55 (61)   35 (39)                 31 (46)   37 (54)                                                                 
  Tumor size (cm)            \< 3      212           46 (66)   24 (34)   9.713        **0.002**      200   30 (52)   28 (48)   0.097     0.755   
  ≥ 3                        61 (43)   81 (57)                 70 (49)   72 (51)                                                                 

. *TMEM88* and NSCLC survival {#s03.03}
-----------------------------

To evaluate the association between *TMEM88* methylation and overall survival, we performed Kaplan-Meier survival analysis on 213 patients with NSCLC. The analysis showed that patients with high *TMEM88* methylation had a shorter overall survival (median survival of 46 months) than those with low *TMEM88* methylation (median survival \>59 months, *P*=0.021) (**[Figure. 1C](#Figure1){ref-type="fig"}** and **[Table 2](#Table2){ref-type="table"}**). This survival association with *TMEM88* methylation in NSCLC remained significant after the adjustment for covariates and potential confounding factors (**[Table 2](#Table2){ref-type="table"}**). However, no association was observed between *TMEM88* expression and overall survival in the study (**[Table 2](#Table2){ref-type="table"}**).

###### 

Cox regression analysis of overall survival and patient characteristics

  Variable                   Univariate                         Multivariate                            
  -------------------------- ------------------- -------------- ------------------- ------------------- -------
  Age                        1.53 (1.06--2.20)   **0.023**                          1.51 (0.96--2.37)   0.077
  Gender                                                                                                
  　Male                     1.00                0.672          1.00                0.484               
  　Female                   1.08 (0.75--1.56)                  0.80 (0.44--1.48)                       
  Smoking status                                                                                        
  　No                       1.00                0.241          1.00                0.211               
  　Yes                      0.80 (0.56--1.16)                  0.67 (0.36--1.26)                       
  Stage                                                                                                 
  　I--II                    1.00                **\< 0.001**   1.00                **\< 0.001**        
  　III--IV                  4.18 (2.86--6.10)                  3.44 (2.18--5.44)                       
  Family history of cancer                                                                              
  　No                       1.00                0.341          1.00                0.519               
  　Yes                      1.25 (0.79--1.97)                  1.21 (0.68--2.17)                       
  *TMEM88* methylation                                                                                  
  　Low                      1.00                **0.021**      1.00                **0.018**           
  　High                     1.57 (1.07--2.38)                  1.74 (1.10--2.74)                       
  *TMEM88* expression                                                                                   
  　Low                      1.00                0.521          1.00                0.940               
  　High                     0.88 (0.60--1.30)                  0.98 (0.63--1.53)                       

. *TMEM88* expression in NSCLC cell lines after DAC treatment {#s03.04}
-------------------------------------------------------------

To assess the functional relevance of *TMEM88* methylation in NSCLC, we analyzed the methylation changes related to *TMEM88* expression after the treatment of the NSCLC cell lines A549 and H1299 with the demethylation agent, DAC. Our experiments showed that DAC treatment reduced *TMEM88* methylation and resulted in elevated *TMEM88* expression in both cell lines (**[Figure. 2A](#Figure2){ref-type="fig"}**).

![](cbm-14-4-377-2){#Figure2}

![Demethylation of *TMEM88* by DAC and cell migration, invasion, proliferation, and cell cycle.](cbm-14-4-377-2-1){#Figure2-1}

. DAC-induced *TMEM88* expression and NSCLC cell behavior {#s03.05}
---------------------------------------------------------

To evaluate the effect of *TMEM88* expression on NSCLC cells, we performed a number of *in vitro* experiments. First, we investigated cell migration and invasion after the DAC-induced upregulation of *TMEM88* expression in H1299 and A549 cells that originally had a low expression and high methylation of *TMEM88*. The experiments showed that the demethylation of *TMEM88* in H1299 and A549 significantly delayed cell migration (**[Figure. 2B](#Figure2){ref-type="fig"}**). Moreover, the invasion ability of H1299 and A549 cells was also significantly decreased (*P* \< 0.05 and *P* \< 0.01, respectively) after demethylation treatment ( **[Figure. 2C](#Figure2){ref-type="fig"}**). In order to further validate the effect of *TMEM88* expression on NSCLC cells, we transfected the cells with *TMEM88* siRNA after DAC treatment, which reduced *TMEM88*. The experiments showed that the demethylation of *TMEM88* in H1299 and A549 significantly delayed cell migration (**[Figure. 2C](#Figure2){ref-type="fig"}**), but that these effects were abolished when the cells were transfected with *TMEM88* siRNA.

We then analyzed cell proliferation and cell cycle progression after DAC treatment. Cell proliferation in DAC-treated H1299 cells was decreased by 60% in comparison with the untreated cells (*P* \< 0.01). Proliferation of A549 cells was also decreased, but the change was not statistically significant ( **[Figure. 2D](#Figure2){ref-type="fig"}**). Therefore, the demethylation of *TMEM88* retarded cell cycle progression at the G2/M phase in both cell lines (**[Figure. 2E](#Figure2){ref-type="fig"}**).

. Correlation between *TMEM88* and molecules in the Wnt signaling pathway {#s03.06}
-------------------------------------------------------------------------

*TMEM88* was reported to inhibit canonical Wnt/β-Catenin signaling through interaction with the Wnt pathway factor Dishevelled (*DVLS*)^[@b14]^ As an inhibitor of the Wnt signaling, *TMEM88* may interact with the molecules in the signaling pathway. To determine whether the expression of *TMEM88* was correlated with the genes involved in Wnt/β-Catenin signaling, we analyzed data from TCGA. We downloaded freely available gene expression data from lung cancer samples and calculated expression correlations between *TMEM88* and several components in the Wnt/β-Catenin signaling pathway, such as Wnt, Frizzled class receptor (*FZD*), Receptor tyrosine kinase like orphan receptor (*ROR*), and Dishevelled segment polarity protein (*DVL*). Modest correlations were found between *TMEM88* expression and some of these genes, including *DVL1* (*r*=0.21), *FZD4* (*r*=0.27), *FZD5* (*r*=0.39), and *ROR1* (*r*=0.30) (**[Table 3](#Table3){ref-type="table"}**).

###### 

Pearson correlation coefficients between the expression of *TMEM88* and the genes involved in the Wnt signal pathway in TCGA.

  -----------------------------------------------------------------------------------------
  Gene symbol   Description                                       *P*        Pearson χ^2^
  ------------- ------------------------------------------------- ---------- --------------
  *DVL1*        Dishevelled segment\                              \< 0.001   0.206
                polarity protein 1                                           

  *DVL2*        Dishevelled segment\                              \< 0.050   0.102
                polarity protein 2                                           

  *DVL3*        Dishevelled segment\                              \< 0.050   --0.107
                polarity protein 3                                           

  *FZD10*       Frizzled class receptor 10                        \< 0.050   --0.101

  *FZD2*        Frizzled class receptor 2                         \< 0.010   0.139

  *FZD4*        Frizzled class receptor 4                         \< 0.001   0.266

  *FZD5*        Frizzled class receptor 5                         \< 0.001   0.390

  *FZD7*        Frizzled class receptor 7                         \< 0.050   --0.124

  *FZD8*        Frizzled class receptor 8                         \< 0.010   0.138

  *ROR1*        Receptor tyrosine kinase like orphan receptor 1   \< 0.001   0.301

  *WNT5A*       Wnt family member 5A                              \< 0.010   --0.155
  -----------------------------------------------------------------------------------------

. Discussion {#s04}
============

Our study demonstrated that the *TMEM88* promoter was highly methylated in NSCLC and that this hypermethylation was correlated with a low expression of *TMEM88*. The survival analysis showed that patients with NSCLC and methylated *TMEM88* had poor overall survival compared with those without methylated *TMEM88*. In addition, patients with higher *TMEM88* expression had a longer survival time in more than 36 months survival group (*P*\>0.05). Furthermore, our*in vitro* experiments revealed that *TMEM88* expression was increased after the treatment of NSCLC cells with the demethylation agent DAC; the treatment also inhibited cell proliferation, migration, and invasion, which indicated that our observations in patients were biologically relevant. These findings suggested that promoter methylation of *TMEM88* may serve as a potential biomarker for NSCLC prognosis and treatment.

*TMEM88* is a transmembrane protein located on the cell membrane of *Xenopus* embryonic cells^[@b18]^. As a newly discovered gene, limited studies have been conducted on *TMEM88*. Although the mechanism is not fully understood, evidence has suggested that *TMEM88* may play an important role in the regulation of human stem cell differentiation and embryonic development and have significant involvement in cell signaling^[@b3]^. However, no studies have previously shown that *TMEM88* methylation is implicated in lung cancer prognosis.

Many genes have been reported to undergo aberrant DNA methylation in cancer^[@b19],[@b20]^, such as the DNA repair gene O(6)-methylguanine DNA methyltransferase (*MGMT*) in B-cell lymphoma^[@b21]^, dickkopf 3 (*Dkk3*) gene in gastric cancer^[@b22]^, secreted frizzled-related protein 1 (*SFRP1*) in breast cancer^[@b23]^ and colorectal cancer^[@b24]^, *MGMT* and *MLH1* in colorectal cancer^[@b25]^, and *WIF-1*^[@b26]^ and *Axin*^[@b27]^ in lung cancer. In our study, we discovered that the hypermethylation of *TMEM88* in NSCLC was associated with an unfavorable prognosis. In addition to our findings, Mullapudi et al.^[@b28]^ performed a genome-wide analysis of the lung cancer methylome and identified the hypermethylation of *TMEM88*. Lee et al.^[@b26]^ demonstrated that promoter methylation of Wnt inhibitory factor 1 (*Wif1*) was an early and frequent event and the hypermethylation of Wif1 was an indicator of the unfavorable prognosis of non-small cell lung cancer. Hypermethylated Axin was also correlated with the progression of lung cancer^[@b27]^. Zhang et al.^[@b23]^ revealed that the hypermethylation of frizzled-related protein 1 (*SFRP1*) was a common contributory factor in lung carcinogenesis and could serve as a potential biomarker for NSCLC in the Chinese population.

In our study, we demonstrated that *TMEM88* expression level was increased after the demethylation treatment of NSCLC cells and that the treatment resulted in the inhibition of cell migration, invasion, and proliferation. These results suggested that *TMEM88* may behave as a tumor suppressor in NSCLC and that the hypermethylation of *TMEM88* in NSCLC may be associated with an unfavorable prognosis. Previous studies have suggested that the activation of the Wnt signaling pathway promotes tumorigenesis^[@b29]^; conversely, the inhibition of Wnt signaling suppresses this process^[@b3]^. Our analysis of online data also indicated that *TMEM88* expression was correlated with some of the molecules involved in the Wnt signaling pathway. *TMEM88* inhibits Wnt/β-Catenin signaling through interaction with the Wnt pathway factor Dishevelled (*DVLS*)^[@b14]^. Therefore, the hypermethylation of the *TMEM88* gene may inhibit its function as a negative modulator of Wnt/β-Catenin signaling, which results in the constitutive activation of this signal pathway in NSCLC^[@b30]^. This may explain why the hypermethylation of *TMEM88* in NSCLC is associated with an unfavorable prognosis. There is evidence to demonstrate that promoter hypermethylation inactivates various Wnt pathway inhibitors, such as *WIF-1*^[@b26],[@b31]^, *sFRP-1*^[@b12]^, *sFRP-5*^[@b32]^, and *Dkk-3*^[@b33]^, which are also associated with poor prognosis. Therefore, we concluded that the Wnt/β-Catenin signaling pathway was important in NSCLC biology and prognosis and *TMEM88* act as an inhibitor of this signal pathway. Further, the methylation of *TMEM88* may serve as a potential biomarker for Wnt/β-Catenin signaling when the pathway is targeted for therapy.

Recently, Zhang et al.^[@b14]^ suggested that the presence of the *TMEM88* protein in the cytosol of NSCLC cells could promote cell invasion and metastasis through the activation of the p38-GSK3ß-Snail signal pathway. However, our study suggested that *TMEM88* had high methylation and low expression in tumors compared with normal tissues and that demethylation treatment could inhibit the invasion and migration of NSCLC cells (**[Figure. 1](#Figure1){ref-type="fig"}** and **[2](#Figure2){ref-type="fig"}**). Jang et al.^[@b34]^ demonstrated that mir-708 could promote the invasion of NSCLC cells through the suppression of the expression of *TMEM88*, which suggested that *TMEM88* may be a tumor suppressor. Furthermore, the expression of *TMEM88* in 58 tumor samples and matched adjacent non-tumor tissues in the TCGA database was 25.27±12.58 and 171.88±97.04, respectively (*P* \< 0.0001), which supported the behavior of *TMEM88* as a tumor suppressor. Studies have also suggested that *TMEM88* may have different forms of molecules, which are located in different cellular compartments and have different functions and activities^[@b14],[@b15]^. Thus, more studies are needed to clarify the role of *TMEM88* in lung cancer.

In summary, we observed that the epigenetic silencing of *TMEM88* by promoter methylation was associated with a poor prognosis of NSCLC and that *TMEM88* could inhibit cell proliferation, migration, and invasion. These findings suggested that *TMEM88* may function as a tumor suppressor and serve as a potential biomarker for NSCLC prognosis and treatment.
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